Approval

Beijing Fuyuan gets Chinese nod for generic extended-release upadacitinib

China cleared Beijing Fuyuan Pharmaceutical's copy of upadacitinib, and the approval counts as passing the generic consistency evaluation. Upadacitinib sales in tracked Chinese markets neared RMB 1 billion in 2025 after 81.74% growth, so generic entry is getting crowded. Fuyuan has now logged 23 product approvals this year and spent about RMB 8.54 million developing this one.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call